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Background: Isolated hepatic perfusion with high-dose chemotherapy is a treatment option
for patients with irresectable metastases confined to the liver. Prolonged local control and
impact on survival have been claimed. Major drawbacks are magnitude and costs of the
procedure. We developed an isolated hypoxic hepatic perfusion (IHHP) with retrograde
outflow without the need for a heart-lung machine.
Patients and Methods: Twenty-four consecutive patients with irresectable metastases of
various origins were treated. IHHP inflow was via the hepatic artery, outflow via the portal
vein with occlusion of the retrohepatic caval vein. Radiolabeled albumine was used for leakage
monitoring. Melphalan was used at 1–2 mg/kg. A 25-minute perfusion period was followed by
a complete washout. Local and systemic melphalan concentrations were determined.
Results: Compared with oxygenated classical IHP, the IHPP procedure reduced operation
time from >8 h to 4 hours, blood loss from >4000 to 900 cc and saved material and per-
sonnel costs. Leakage was 0% with negligible systemic toxicity and 0% perioperative mor-
tality. Tumor response: complete response (CR) in 4%, partial response (PR) in 58%, and
stable disease (SD) in 13%. Median time to progression was 9 months (2–24 months);
pharmacokinetics demonstrated intrahepatic melphalan concentrations more than 9 fold
higher than postperfusion systemic concentrations.
Conclusions: IHPP is a relatively simple procedure with reduced costs, reduced blood loss,
no mortality, limited toxicity, and response rates comparable to classic IHP. The median
duration of 9 months of tumor control should be improved. Hereto, vasoactive drugs, will be
explored in further studies.
Key Words: Isolated hepatic perfusion—Retrograde outflow—Hypoxic—Metastasis—Melpha-
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Approximately 50–60% of colorectal cancer pa-
tientswill develop livermetastases during follow-up. In
nearly a quarter of these patients the liver is the only
site of disease.1 If hepatic metastases of colorectal
cancer are resectable, 5-year survival rates are reported
between 25% and 45% depending on several prog-
nostic factors.2 Patients with irresectable hepatic
metastases have a 0–2% 5-year survival rate and a
median survival of 10 months without treatment.3
Therefore, aggressive, selective treatment of the liver
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seems justified since control of hepatic metastases
translates into improved overall survival. Despite the
increasing response rates with systemic chemothera-
peutic agents such as oxaliplatin and irinotecan in
combination with 5-FU and the promising results with
the addition of angiogenesis inhibitors,4 overall sur-
vival remains poor.5,6 In order to improve responses
and survival, locoregional chemotherapeutic regi-
ments have been developed. These therapies include
hepatic arterial embolization, intratumoral injections
of ethanol, acetic acid, biological agents, stereotactic
or intra-arterial radiotherapy, intralesional laser ther-
apy, cryotherapy, radiofrequency ablation, and re-
gional infusion or perfusion of chemotherapeutic
drugs. The best approach for regional infusion of
chemotherapeutics in the liver is unknown. Hepatic
artery infusion (HAI), hepatic artery ligation with he-
patic artery and portal vein infusion, or portal vein
infusion have all been attempted. Of these modalities,
HAI is the most widely applied form. A number of
studies have been conducted comparing systemic che-
motherapy with HAI, and a modest but significant
improvement of survival was demonstrated by HAI in
a meta-analysis.7–9
In a leakage-free perfusion setting, isolated hepatic
perfusion (IHP) shields the systemic compartment to
drug exposure, and in combination with a washout
procedure it protects against systemic toxicity. Clin-
ical studies using melphalan with or without tumor
necrosis factor alpha (TNF) have shown promising
results.10–17 However, IHP is a major, complex,
expensive, and time-consuming operation. These
features in combination with hepatic and systemic
toxicity are major drawbacks toward wide clinical
application. Our aim was to develop an IHP that is
easy to perform, with limited morbidity or mortality,
not time consuming, and with minimal costs of the
operation without affecting the antitumor efficacy.
We started an isolated hypoxic hepatic perfusion
(IHHP) technique with percutaneously placed bal-
loon catheters and retrograde outflow without a
heart-lung machine and extracorporeal venovenous
bypass in pigs.18 In a recent study, we demonstrated
the feasibility of this technique (retrograde outflow of
the liver) in a clinical setting.17 A major drawback of
the technique was 38% systemic leakage rate. On the
basis of these results, we modified the technique by
applying an ‘‘open’’ surgical procedure; balloon
catheters are replaced by clamps and all tributaries to
the vena cava such as the adrenal, lumbar, and dia-
phragmatic veins are dissected and ligated. Here we
present the results of the first 24 patients with irre-
sectable liver metastases who underwent an IHHP
with melphalan. The major difference between this
new technique and the classic IHP is that there is no
veno-veno bypass and heart-lung machine involved
and the drainage of the liver is retrograde through the
portal vein.
MATERIALS AND METHODS
Patient Selection Criteria
Inclusion criteria were as described previously.17 In
all patients a radical resection of the primary tumor
was performed prior to entering the study protocol
except for one patient with hepatic metastasis of
unknown primary. The liver metastases were con-
sidered irresectable, on the basis of multiple lesions in
multiple segments of the liver and/or location near
vascular structures. Tumor involvement had to be
less than 50% of the total liver volume to prevent
massive necrosis in case of a response. Absence of
extra hepatic tumor growth was evaluated by com-
puted tomography (CT) scan of thorax and abdo-
men. All patients had a Karnofsky performance score
of at least 90, liver enzymes (ALAT, ASAT and AF)
not higher than five times the normal values, and
bilirubin not higher than two times the normal val-
ues. Exclusion criteria included: age younger than 18
or older than 70, portal hypertension, significant
central nervous system disease, significant cardio-
vascular, pulmonary or renal disease, uncontrolled
infections, presence of organ grafts, and chemother-
apy or radiation therapy within 4 weeks prior to the
IHHP. Routinely, an angiography was performed to
exclude aberrant hepatic arteries or to visualize other
anatomic anomalies. The study protocol was ap-
proved by the Medical Ethical Committee of the
Erasmus University Medical Centre, and written in-
formed consent was obtained from all patients.
Perfusion Circuit
Perfusion sets (PfM, GmbH, Cologne, Germany)
consisted of a tubing set with a volume of 220 mL,
containing a bubble trap. All IHHPs were performed
with inflow via the hepatic artery and outflow via
portal vein. In the perfusion circuit, flow was main-
tained by a roller pump and pressure was measured
via a sideline.
Drugs
A dosage of 1 mg/kg melphalan (L-Pam, Alkeran,
Wellcome Ltd. London, UK) was used in 20 of the 24
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patients and infused through a sideline into the per-
fusion circuit. Two times 1.5 mg/kg melphalan and
two times 2.0 mg/kg was used. In the first eight pa-
tients, a bolus infusion was used. In the last 16 pa-
tients, a 10-minute pump infusion was used. The total
perfusion (10-minute infusion included) with mel-
phalan was conducted for 20 to 30 minutes.
Surgical Procedure of the Retrograde Flow IHHP
A right subcostal incision was performed, and the
liver was mobilized from its retroperitoneal and dia-
phragmatic attachments. A prophylactic cholecys-
tectomy was not performed routinely. Tributaries to
the vena cava such as the adrenal, lumbar, and dia-
phragmatic veins were dissected and ligated. The
vena cava was isolated and clamped above and below
the liver, respectively, to prevent venous leakage. The
portal vein, proper hepatic artery, and gastroduode-
nal artery were dissected, and the hepatic artery
cannulated via the gastroduodenal artery with an 8 F
catheter for inflow of the perfusate. In two patients,
an aberrant left hepatic artery, coming from the left
gastric artery was cannulated together with the
proper hepatic artery for inflow. The portal vein was
cannulated with a 14 F catheter for outflow. Patients
subsequently received 2 mg/kg heparin. The hepatic
artery catheter and the portal vein catheter were
connected to the perfusion circuit primed with
220 mL Haemaccel (Behring Pharma, Amsterdam,
The Netherlands). After clamping of the caval vein
superior and inferior of the liver, clamping of the
aorta just beneath the diaphragm, clamping the
portal vein just above the pancreas, clamping the
proper hepatic artery just proximal of the gastrodu-
odenal branch, and clamping of the common bile
duct with its surrounding tissue, the retrograde iso-
lated perfusion was performed. The retrograde per-
fusion setup is depicted in Fig. 1.
The perfusate was circulated by a constant flow.
Stable perfusion was monitored by pressure mea-
surement and the perfusate level in the bubble trap.
Hereafter, melphalan was infused into the circuit and
the perfusion was conducted for 20 to 30 minutes.
Thereafter, a washout procedure was performed by
1 L of Haemaccel collecting the venous effluent. To-
tal liver ischemia time never exceeded 60 minutes.
The isolation was terminated by relief of the
clamps on the caval vein followed by the relief of the
aortic clamp, controlling systemic blood pressure.
The catheter in the hepatic artery could be removed
and the gastroduodenal artery could be ligated fol-
lowed by decanulation and closing the venotomy of
the portal vein. In case of an aberrant left hepatic
artery, this artery was ligated after removal of the
catheter.
Leakage Monitoring
During IHHP, potential leakage of drugs was
monitored using a radioactive tracer. A small cali-
bration dose of human serum albumin radiolabeled
with 131I was injected into the systemic circulation
prior to the perfusion and 10-fold higher dose of the
same isotope was injected into the isolated hepatic
perfusion circuit. Continuous monitoring was per-
formed with a precordial scintillation probe. Systemic
leakage is expressed quantitatively as a percentage
(100% leakage representing a homogeneous distri-
bution of the isotope in the body).14
Blood Sampling
Before, during, and after the perfusion blood
samples were taken and collected to study pharma-
cokinetics of melphalan and hematological, renal,
hepatic, and gastrointestinal toxic side effects. Tox-
icity is graded according to the standardized WHO
common toxicity criteria.19
Measurement of Melphalan Concentrations
Melphalan was measured in plasma by gas chro-
matography–mass spectrometry (GC-MS). P-[Bis(2-
chloroethyl)amino]-phenylacetic acid methyl ester
was used as an internal standard. Samples were ex-
tracted over trifunctional C18 silica columns. After
elution with methanol and evaporation, the com-
pounds were derivatized with trifluoroacetic anhy-
dride and diazomethane in ether. The stable derivates
were separated on a methyl phenyl siloxane GC
FIG. 1. The retrograde perfusion setup.
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capillary column and measured selectively by single
ion monitoring GC-MS in the positive EI mode de-
scribed earlier by Tjaden et al.20
Assessment of Tumor Response
This was done by comparing pre-perfusion CT
and/or MRI scans of the liver with scans made at 8–
10 weeks after IHHP. The tumor marker carcino-
embryonic antigen (CEA) was monitored (when
indicated) preoperatively and 8–10 weeks postperfu-
sion, but was not used for response assessment.
Clinical responses are assessed by standardized WHO
criteria.19
RESULTS
Patient Characteristics (Table 1)
In a total of 24 consecutive patients, 13 males and
11 females with a median age of 57 years (range, 41–
70) were included in the protocol. Eighteen patients
had irresectable metastases of colorectal origin, four
ocular melanomas, one sarcomas, and one unknown
primary hepatic metastases.
Operation Characteristics
Median operation time was 240 minutes (150–
300 minutes), including perfusion time. Median
blood and fluid loss was 900 mL (300–3200 mL). In
the first eight patients, melphalan was administered
as a bolus into the isolated liver circuit. The last 16
patients received a 10-minute pump infusion of mel-
phalan. The perfusion (10-minute infusion included)
with melphalan was conducted for 20 to 30 minutes.
Perioperative mortality (<90 days) was 0%. Median
hospital stay was 9 days (5–29 days).
Leakage Control
All IHHPs were leakage free during the perfusion
except in one patient, where 2% systemic leakage was
measured. When this perfusion was finished, it ap-
peared that in this patient there was an insufficient
clamping of the suprahepatic caval vein. After
washout of the isolated circuit with Haemaccell, a
median of 7% (4–10%) leakage into the systemic
TABLE 1. Characteristics of 24 patients with irresectable liver metastases treated by IHHP with retrograde outflow via portal
vein with melphalan
PT
Tumor
primary
Progressive on
chemotherapy
Toxicity
Response after
perfusion
Time to progr.
(months) Status
Months after
perfusionHepato Blood Renal
1 CRC No 1 0 0 CR 10 Alive 46
2 CRC No 1 0 0 PR 24 Dead 38
3 CRC Yes 1 4 0 SD 12 Dead 42
4 CRC No 1 0 0 PR 6 Dead 29
5 CRC No 1 3 0 PR 20 Dead 32
6 EM No 1 0 0 PR 5 Dead 9
7 SARC No 1 3 0 PR 13 Dead 17
8 CRC No 2 0 0 PR 9 Dead 9
9 CRC Yes 1 0 0 SD 12 Dead 37
10 CRC Yes 1 0 0 PD 2 Dead 10
11 CRC No 1 0 0 PR 9 Dead 29
12 CRC No 1 0 0 PD 9 Dead 18
13 CRC No 1 0 0 PD 2 Dead 8
14 CRC Yes 1 0 0 PR 4 Dead 18
15 EM No 1 0 0 PR 5 Dead 6
16 CRC No 1 2 0 PR 9 Alive 29
17 UP Yes 1 3 0 PD 2 Dead 5
18 EM No 1 0 0 PR 9 Dead 20
19 CRC No 2 2 0 PR 4 Dead 6
20 CRC No 1 0 1 PR 5 Dead 5
21 EM No 1 2 0 PR 13 Dead 15
22 CRC Yes 1 0 0 PD 4 Dead 6
23 CRC Yes 1 0 0 SD 5 Dead 6
24 CRC Yes 1 0 0 PD 9 Alive 11
PT, patient number; CRC, colorectal cancer; CR, complete response; SARC, sarcoma; PR, partial response; EM, eye melanoma; SD, stable
disease; UP, unknown primary; PD, progressive disease.
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circuit was demonstrated by continued monitoring
until the end of the operation.
Toxicity Study (Table 1)
Hepatic toxicity consisted mainly of a transient rise
of liver enzymes during the first week after IHHP.
WHO grade I occurred in 92% of the patients (22 of
24) and WHO grade II in 8% of the patients (2 of 24).
Three patients experienced bile duct necrosis (dis-
cussed in detail in the section ‘‘Complications’’). No
other hepatic toxicities occurred (no coagulopathy
was observed). Systemic toxicity was mainly leuco-
penia, WHO grade I–III in 25% (6 of 24), and severe
grade IV leucopenia in one patient (4%) after per-
fusion. Two of these patients received G-CSF
(Neupogen, Amgen B.V., Breda, The Netherlands).
One patient received prophylactic G-CSF. Eighteen
patients (71%) did not develop leucopenia. No renal
(except for one patient grade 1) or gastrointestinal
toxicity was observed.
Melphalan Pharmacokinetics
Figure 2 shows a drug concentration vs time curve
in the isolated circuit in a patient with a pump infu-
sion. The area under the concentration versus time
curve (AUC) calculation showed a regional concen-
tration of 2382 (lg · min/mL) versus undetectable
systemic that makes the ratio AUC regional/systemic
infinite (Fig. II). The median peak regional melpha-
lan concentration was 68.04 lg/mL (range, 42.3–
256.99) and negligibly low to undetectable systemic
concentrations. After washout and subsequent
releasing of the clamps, median peak systemic 4.2 lg/
mL (range, 3.00–18.33) melphalan concentrations
were observed. The AUC calculation showed a sys-
temic concentration of 275 lg · min/mL after
washout. Thus, intrahepatic melphalan concentra-
tions during the IHHP are >9 fold higher than the
post-IHHP systemic melphalan concentrations.
Complications
In three patients, bile duct necrosis occurred
(Fig. 3). One of these patients was asymptomatic, and
bile duct necrosis was found on routine CT scan
during follow-up. Two of the patients with bile duct
necrosis developed fever. No other explanation could
be found for the fever, besides the intrahepatic
‘‘bilomas,’’ and therefore one patient was treated
with percutaneous drainage and endoscopic stent
placement in ductus choledochus. The other patient
with fever received antibiotics. Both patients recov-
ered, and slight elevations of bilirubin persisted,
without complaints. In the first eight patients mel-
phalan was administered as a bolus into the isolated
liver circuit. After four patients melphalan dose was
increased to 1.5 mg/kg in two patients and to 2 mg/
kg melphalan in another two patients. Three of these
patients (37.5%) developed bile duct necrosis, which
is why the other 16 patients were treated with 1 mg/
kg melphalan using a 10-minute pump infusion into
the circuit. Bile duct necrosis did not occur in these
patients. Postoperative chemical cholecystitis was not
demonstrated.
Tumor Response and Patient Survival (Table 1)
In one patient a complete response was observed
(4%). Partial response (PR) was seen in 14 patients
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FIG. 2. Drug-concentration versus time curve.
FIG. 3. Intra-hepatic bile duct necrosis after IHHP
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(58%), and stable disease (SD) was demonstrated in
three patients (13%). Overall, a clinical response rate
of 62% and a clinical benefit of nonprogression in
75% were observed. Six patients developed progres-
sive disease (25%). Progressive disease occurred with
median interval after IHHP of 9 months (range 2–
24 months). Sixteen patients had progression of the
liver tumors during follow-up. Fourteen patients
developed extrahepatic disease during follow-up. To
analyze the response rates and survival, it may be
more opportune to include only the 18 patients with
colorectal liver metastases. Median follow-up was
18 months. Median patient survival for patients with
colorectal liver metastases (n = 18) was 18 months
(range, 5–46 months). Median time to progression
was 9 months (2–16 months). Seven of these 18 pa-
tients experienced failures of systemic chemotherapy.
Two patients (PtNo 3 and 23) were progressive on the
combination of 5-fluorouracil (5FU) and oxaliplatin
(FOLFOX) (10 and 6 cycles, respectively), two pa-
tients (PtNo 9 and 10) were progressive on 5-FU and
leucovorine (22 and 16 cycles, respectively), one pa-
tient (PtNo 14) was progressive after Xeloda (four
cycles) and irinotecan (four cycles), one patient (PtNo
24) after six cycles of FOLFOX and four cycles of
irinotecan, and one patient (PtNo 22) was progressive
after Xeloda (six cycles), irinotecan (six cycles), and
combination of Xeloda and oxaliplatin (XELOX)
(eight cycles). Median survival for patients with
colorectal liver metastases, not treated with chemo-
therapy before IHP (n = 11), was 29 months (range,
5–46 months).
DISCUSSION
Isolated liver perfusions are only performed by a
few centers worldwide, demonstrating promising
antitumor effects; however, the technique is a major,
complex, expensive, and time-consuming operation.
In the present study we describe an alternative tech-
nique using a retrograde hepatic flow in an isolated
hypoxic hepatic perfusion (IHHP) system. The tech-
nique was performed in 24 patients and demonstrated
to be safe, with minimal morbidity and no morbidity.
Overall response rate was 62% with no progression in
75%, and median time to progression of disease was
9 months.
The magnitude of the standard isolated liver per-
fusion technique is well demonstrated in two recently
published series by the centers with the largest expe-
rience in IHP (NCI, Bethesda, MD, USA, and
LUMC, Leiden, The Netherlands, respectively).11,15
Median IHP operation time was reported to be more
than 8 hours (range, 5.8–14.7 hours). In the study of
Bartlett et al.11 the estimated blood loss was 2.2 L
(range, 0.8–4.5 L), and Rothbarth et al.15 reported a
range of 0.9–10 L (median not given, older series
mean of 4.4 L). Mortality (<30 days) occurred in
both series with 5.6% in the Leiden series (n = 71)
and 4% in the NCI series (n = 124). Classical IHP
uses a venovenous bypass and a heart-lung machine,
which is a time-consuming procedure necessitating a
specialized perfusion team. In the present study a
modification was developed, allowing a safe perfusion
in a shorter operation time (median duration, 4 hour),
with less blood loss (median, 900 cc), reducing mor-
bidity and without mortality, without the need of a
heart-lung machine or venovenous bypass.
The absence of mortality (<90 days) in the present
study can be explained by the smaller number of
patients and/or patient selection. However, it may
well be related to the smaller magnitude of the
operation and the corresponding decreased operation
time and blood loss. Median hospital stay was 9 days
(range, 5–29), which was also shorter than the 12 and
11 days in the aforementioned studies.11,15
Hepatic toxicity is remarkably low in the present
series except for three patients who developed bile
duct necrosis (Table 1). High peak concentrations of
melphalan in the isolated circuit might explain the
bile duct necrosis that was observed in patients who
were perfused with higher melphalan concentrations.
In a preclinical study, the occurrence of severe chol-
angiofibrosis was strongly dependent on the mel-
phalan concentration.21 The study also demonstrated
that tumor response was not affected by melphalan
peak concentration, but by the total dose of mel-
phalan. Therefore, to prevent high peak concentra-
tions keeping the same concentration of melphalan,
bolus infusions were replaced by a 10-minute pump
infusion. This resulted in the absence of bile duct
necrosis in the last 16 perfused patients.
The maximum period of 60-minute hypoxia did not
seem to result in extrahepatic and/or systemic toxic-
ity. Moreover, clamping of the aorta just underneath
the diaphragm for a maximum of 60 minutes did not
lead to renal and/or gastrointestinal morbidity.
To overcome the use of a venovenous bypass and
heart-lung machine, we performed a hypoxic perfu-
sion. The use of hypoxia might also enhance the
antitumor effect. Hypoxia renders tumor cells more
sensitive to cytostatic agents in general and enhances
the antitumor effects of drugs such as melphalan.22,23
Changing the perfusion direction may reduce liver
toxicity, without affecting the antitumor efficacy as
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described by Rothbarth et al.24 An animal study
demonstrated an unaffected tumor uptake and a re-
duced liver uptake by 80% in an IHP model with
arterial inflow and retrograde portal outflow.25 This
may explain our remarkably low hepatic toxicity in
the present series using retrograde outflow in a clin-
ical setting.
In the large IHP series of patients with colorectal
liver metastasis, response rates of 74% and 59%,11,15
respectively, are reported, which is in line with the re-
sponse rate in the present study. The median time to
progression in these IHP studies was 14.5 and
7.7 months, respectively. The time to tumor progres-
sion of 9 months after IHHP seems to be comparable
to these numbers. Alexander et al. published their re-
sults in patients with progressive disease after irino-
tecan-based therapies, and still a response rate of 60%
was obtained after IHP with melphalan.16 The 2-year
survival was 28% with a 12-month median survival.
Although interpretation and comparison of the results
from these different studies are difficult, the results of
the retrograde IHHP technique described here are
similar. In the past 10 years, new anticancer agents
(oxaliplatin and irinotecan) have increased the re-
sponse and survival rates. The addition of targeted
therapies (cetuximab and bevacuzimab) may increase
the response rates more than 70%. Especially in this
era of exciting developments, tailored treatment to
increase individual survival rates while keeping the
toxic effects to a minimum is challenging. The role of
IHP in colorectal livermetastases has been discussed in
recent reviews.24,26,27 The promising results of the IHP
studies in the past years cannot be disregarded. It is
conceivable to combine IHP with adjuvant treatment
strategies to reduce the recurrence rate, which is the
major determinant of the survival rate after IHP.
Continuing locoregional treatment by HAI after an
IHP procedure is technically feasible and appears to
prolong the duration of the response and survival in
patients with colorectal hepatic metastases.11 Of the 18
patients with colorectal liver metastases in the present
series, 10 developed extrahepatic disease, suggesting
the need for additional systemic treatment. Duration
of tumor control needs to be improved.To achieve this,
the addition of vasoactive drugs, identified in our
laboratory to have synergistic activity in combination
withmelphalan by significantly increasing drug uptake
in the metastases, will be explored in further stud-
ies.28,29At this time, IHHPshould be reserved for those
patients who are progressive on standard chemother-
apy protocols. When responses in future trials are
improved, this techniquemight be optional for patients
who prefer a single procedure, which could potentially
lead to similar results asmultiple courses of systemic or
intra-arterial chemotherapy. Leaving behind at the end
of the IHHP a port-a-cath system for subsequent HAI
in case of (re)progression should also be considered as
a strategy to further improve prolonged locoregional
tumor control.
In ocular melanoma, the liver is the only organ site
involved in 70–80% of patients and is usually
responsible for death.30,31 The prognosis of a patient
with hepatic metastases from uveal melanoma is ex-
tremely poor, with a median survival between 2 and
5 months.32 Partial liver resection is seldom possible.
The therapeutic options are not very effective with
systemic chemotherapy, providing 9% partial re-
sponses and no survival benefit.33,34 There is limited
experience with IHP for hepatic metastases from
uveal melanoma, but the response rates are promis-
ing.35–37 Despite the fact that the experience with
hepatic metastases from uveal melanoma is small in
the present study (n = 4), IHP seems to be an
effective treatment. All four patients died because of
progressive tumor growth and consequent liver fail-
ure after 6, 9, 15, and 20 months. Therefore, espe-
cially in this group of patients, local tumor control is
likely to result in a survival benefit.
CONCLUSIONS
Isolated hypoxic hepatic perfusion with retrograde
outflow via portal vein is a promising technique that
is a relatively simple procedure with reduced blood
loss, no mortality, very limited toxicity, and response
rates comparable to classic, extensive IHP. The
operation time is reduced to 4 hours, without the
need of a heart-lung machine and perfusionists,
which reduces the costs.
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